Condition (MeSH)
Basal Ganglia Cerebrovascular Disease
ClinicalTrials.gov lists 10 trials for Basal Ganglia Cerebrovascular Disease or a narrower condition beneath it. Clearmind Biomedical Inc. has the most among industry and government lead sponsors, with 1.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
When did Basal Ganglia Cerebrovascular Disease trials start? (6)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2
- Phase 3
- Not applicable
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 2 |
| 2024 | 1 |
| 2021 | 2 |
| 2020 | 2 |
| 2019 | 2 |
No forecast is made for this condition: it averages 0.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Basal Ganglia Cerebrovascular Disease trials in? (4)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 1 |
| Not applicable | 5 |
| Observational | 3 |
How many Basal Ganglia Cerebrovascular Disease trials are recruiting? (4)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 2 |
| Completed | 3 |
| Unknown status | 4 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Basal Ganglia Cerebrovascular Disease trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Clearmind Biomedical Inc. | 1 |
Which drugs are being tested for Basal Ganglia Cerebrovascular Disease? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Rivaroxaban | 1 |
| Dabigatran | 1 |
| Edoxaban | 1 |
Interventions as named in the registry (6)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| hUMSCs | 1 |
| Patients will be managed with guideline-based medications | 1 |
| Conservative medical treatment | 1 |
| Standard Medical Treatment | 1 |
| Apixaban IR | 1 |
Showing 5 of 6 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Basal Ganglia Cerebrovascular Disease? (12)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Aneurysms of the Lenticulostriate Artery: A Systematic Review. | World neurosurgery | 2021 | Yes |
| Ruptured lenticulostriate artery aneurysm: a report of a case treated with endovascular embolisation. | BMJ case reports | 2020 | Yes |
| Cerebral Perforating Artery Disease : Characteristics on High-Resolution Magnetic Resonance Imaging. | Clinical neuroradiology | 2019 | Yes |
| Lenticulostriate aneurysms: a case series and review of the literature. | Journal of neurointerventional surgery | 2015 | Yes |
| Lenticulostriate infarction. | Frontiers of neurology and neuroscience | 2012 | Yes |
Showing 5 of 12 publications.
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, and rare-disease identity.